

2013 ONCOLOGY RESEARCH REVIEW



PHM126B
December 2013

Various Analysts
Project Analyst

ISBN: 1-56965-650-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 ABOUT BCC RESEARCH REVIEWS	2
FOREWORD	2
CHAPTER 2 THERAPIES AND DIAGNOSTICS FOR UTERINE CANCER (REPORT HLC142A)	4
INTRODUCTION	4
STUDY GOALS AND OBJECTIVES	4
REASONS FOR DOING THIS STUDY	4
INTENDED AUDIENCE	4
SCOPE OF THE STUDY	5
METHODOLOGY	5
INFORMATION SOURCES	6
ABOUT THE AUTHOR	6
RELATED BCC RESEARCH REPORTS	6
SUMMARY	6
<i>TABLE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>FIGURE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	9
OVERVIEW	9
CANCER	9
<i>TABLE 2 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER</i>	10
GYNECOLOGIC CANCERS	11
ENDOMETRIAL/UTERINE CANCER	11
<i>TABLE 3 KEY CLINICAL FEATURES OF UTERINE CANCER</i>	12
<i>TABLE 4 HISTOLOGY OF ADENOCARCINOMA</i>	13
Causes/Risk Factors	13
Hormone Factors	14
<i>TABLE 5 RISK FACTORS</i>	15
Estrogen	15
Estrogen Therapy	15
Oral Contraceptives	16
Total Number of Menstrual Cycles	16
Pregnancy	16
Obesity	16
Treatment with Tamoxifen	17
Ovarian Tumors	17
Polycystic Ovarian Syndrome	17
Use of an Intrauterine Device	17
Age	17
Diet and Exercise	18
Diabetes	18
Genetics	18
<i>TABLE 6 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC)</i>	18
Breast Cancer	19
Prior Pelvic Radiation Therapy	19
Endometrial Hyperplasia	19

TOPIC	PAGE NO.
Classification	19
Carcinoma	19
<i>TABLE 7 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC GROUPS</i>	19
Sarcoma	20
<i>TABLE 8 CARCINOMA OF THE ENDOMETRIUM</i>	21
Endometrial Cancer Symptoms	21
<i>TABLE 9 SIGNS AND SYMPTOMS</i>	22
Diagnosis	22
Clinical Evaluation	22
<i>TABLE 10 UTERINE CANCER: DIAGNOSIS</i>	22
Tests	23
<i>TABLE 11 DIAGNOSTIC TESTS</i>	23
<i>TABLE 12 STAGES OF ENDOMETRIAL CANCER</i>	23
Pathology	24
Treatment	24
<i>TABLE 13 TREATMENT DEPENDS UPON THE STAGE</i>	25
Uterine Cancer Treatment is Based on Several Important Factors	25
Prognosis	26
Survival Rates	26
<i>TABLE 14 FIVE-YEAR SURVIVAL RATES (%)</i>	27
<i>TABLE 15 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%)</i>	28
Epidemiology	28
Complications	28
Prevention	28
CHAPTER 3 THERAPIES AND DIAGNOSTICS FOR CERVICAL CANCER (REPORT HLC141A)	30
INTRODUCTION	30
STUDY GOALS AND OBJECTIVES	30
REASONS FOR DOING THIS STUDY	30
INTENDED AUDIENCE	30
SCOPE OF THE STUDY	31
METHODOLOGY	31
INFORMATION SOURCES	31
ABOUT THE AUTHOR	32
RELATED BCC RESEARCH REPORTS	32
SUMMARY	32
<i>TABLE 16 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 (\$ MILLIONS)</i>	33
<i>FIGURE 2 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 (\$ MILLIONS)</i>	33
OVERVIEW	34
<i>TABLE 17 MAIN TYPES OF CANCER AND MORTALITY</i>	34
<i>FIGURE 3 MAIN TYPES OF CANCER AND MORTALITY</i>	34
<i>TABLE 18 CANCER: KEY FACTS</i>	35
<i>TABLE 19 PREVENTION STRATEGIES</i>	36
EARLY DETECTION	36

TOPIC	PAGE NO.
EARLY DIAGNOSIS	36
SCREENING	36
<i>TABLE 20 CURRENT SCREENING METHODS</i>	37
CANCER TREATMENT	37
<i>TABLE 21 NONCOMMUNICABLE DISEASES ACTION PLAN</i>	38
CERVICAL CANCER	38
<i>TABLE 22 HISTORY</i>	38
CERVICAL CANCER RESEARCH AND TREATMENT	39
Sentinel Lymph Node Biopsy	39
Human Papillomavirus (HPV) Vaccines	39
Targeted Therapy	40
Hyperthermia	40
Drug Treatment of Precancers	40
SYMPTOMS	40
<i>TABLE 23 CERVICAL CANCER SYMPTOMS</i>	40
<i>TABLE 24 ADVANCED CERVICAL CANCER SYMPTOMS</i>	41
DIAGNOSIS	41
<i>TABLE 25 DIAGNOSIS OF CERVICAL CANCER</i>	41
<i>TABLE 26 RISK FACTORS FOR CERVICAL CANCER</i>	42
TREATMENT	42
<i>TABLE 27 CERVICAL CANCER STAGING</i>	42
PROGNOSIS	43
CHAPTER 4 PREVENTION AND TREATMENT OF PROSTATE CANCER: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM113A)	45
INTRODUCTION	45
STUDY GOALS AND OBJECTIVES	45
REASONS FOR DOING THIS STUDY	45
INTENDED AUDIENCE	45
SCOPE OF THE STUDY	46
METHODOLOGY	46
INFORMATION SOURCES	47
ABOUT THE AUTHOR	47
RELATED BCC RESEARCH REPORTS	47
SUMMARY	47
<i>TABLE 28 GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 (\$ MILLIONS)</i>	49
<i>FIGURE 4 GLOBAL PROSTATE CANCER MARKET, 2010-2017 (\$ MILLIONS)</i>	49
OVERVIEW	50
U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS	51
<i>TABLE 29 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008</i>	52
BIOLOGY OF PROSTATE CANCER	53
PROSTATE GLAND	53
PROSTATE GLAND FUNCTION	54
GROWTH OF THE PROSTATE GLAND	54
TYPES OF PROSTATE CANCER	55
PRECANCEROUS CONDITIONS OF THE PROSTATE	55
PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN)	55
PROLIFERATIVE INFLAMMATORY ATROPHY (PIA)	56

TOPIC	PAGE NO.
PROSTATE CANCER DEVELOPMENT	56
AGING	56
MECHANISMS OF DISEASE DEVELOPMENT PATHOPHYSIOLOGY	57
FAMILY HISTORY	57
ENVIRONMENTAL FACTORS	58
EPIDEMIOLOGY AND RISK FACTORS	58
HORMONES	58
GROWTH FACTORS	59
<i>TABLE 30 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER</i>	60
GENETICS	61
<i>TABLE 31 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI</i>	61
MOLECULAR MECHANISMS OF PROSTATE CANCER	62
<i>TABLE 32 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER</i>	62
The Androgen Receptor	63
PTEN	63
p53	63
GSTP GENES	64
<i>TABLE 33 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION</i>	64
PROSTATE-SPECIFIC ANTIGEN	66
CAVEOLIN-1	66
EMSY	66
AMACR	66
KLF6	66
NBS1	67
CHEK2	67
MISMATCH REPAIR GENES	67
HOXB13	67
BRCA1 AND BRCA2	68
HEREDITARY PROSTATE CANCER	68
PROSTATE CANCER PREVENTION AND TREATMENT	68
CONCLUSIONS	70
CHAPTER 5 THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER (REPORT HLC143A)	73
INTRODUCTION	73
STUDY GOALS AND OBJECTIVES	73
REASONS FOR CONDUCTING THIS STUDY	73
INTENDED AUDIENCE	73
SCOPE OF THE STUDY	74
METHODOLOGY	74
INFORMATION SOURCES	74
ABOUT THE AUTHOR	75
RELATED BCC RESEARCH REPORTS	75
SUMMARY	75
<i>TABLE 34 OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, THROUGH 2018 (\$ MILLIONS)</i>	76
<i>FIGURE 5 OVARIAN CANCER DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2012-2018 (\$ MILLIONS)</i>	76

TOPIC	PAGE NO.
OVERVIEW	77
OVARIAN CANCERS	78
<i>TABLE 35 OVARIAN CANCER FACTS</i>	78
<i>TABLE 36 TYPES OF OVARIAN CANCERS</i>	78
EPITHELIAL TUMORS	78
GERM CELL TUMORS	79
STROMAL TUMORS	79
METASTASIS	79
<i>TABLE 37 OVARIAN TUMORS METASTASIS</i>	79
OVARIAN DISORDERS	79
RISK FACTORS	80
<i>TABLE 38 MAIN RISK FACTORS FOR OVARIAN CANCER</i>	80
<i>TABLE 39 HIGH-RISK FACTORS</i>	81
PREVENTION	81
<i>TABLE 40 PREVENTIVE FACTORS</i>	82
PREVENTIVE STRATEGIES FOR HIGH-RISK WOMEN	82
SYMPTOMS	83
<i>TABLE 41 OVARIAN CANCER SYMPTOMS</i>	83
SIGNS OF CANCER	83
DIAGNOSIS AND SYMPTOM PROGRESSION	84
Early Detection	84
DIAGNOSIS	85
TUMOR MARKERS	85
VITAMIN D AND OVARIAN CANCER	85
PROGNOSIS	86
PROGNOSIS BY STAGE	86
TREATMENT	86
CHEMOTHERAPY	86
TARGETED THERAPY	87
IMMUNOTHERAPY	87
RESEARCH AND NEW DEVELOPMENTS	87
CONCLUSIONS	88
CHAPTER 6 DRUGS AND DIAGNOSTICS FOR HEMATOLOGICAL DISORDERS: GLOBAL MARKET (REPORT PHM116A)	90
INTRODUCTION	90
STUDY GOALS AND OBJECTIVES	90
REASONS FOR DOING THIS STUDY	90
INTENDED AUDIENCE	90
SCOPE OF THE STUDY	91
METHODOLOGY	91
INFORMATION SOURCES	92
ABOUT THE AUTHOR	92
RELATED BCC RESEARCH REPORTS	92
SUMMARY	92
<i>TABLE 42 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017 (\$ MILLIONS)</i>	94

TOPIC	PAGE NO.
<i>FIGURE 6 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017 (\$ MILLIONS)</i>	94
OVERVIEW	94
<i>TABLE 43 KEY BLOOD DISORDERS</i>	95
<i>TABLE 44 MALIGNANT BLOOD DISORDERS</i>	95
<i>TABLE 45 NON-MALIGNANT BLOOD DISORDERS</i>	96
BLOOD DISEASES	97
<i>TABLE 46 TYPE OF BLOOD CELLS AND FUNCTIONS</i>	97
<i>TABLE 47 BLOOD CELLS AND FUNCTION</i>	98
BLOOD DISORDERS	98
ANEMIA	98
Types of Anemia	98
<i>TABLE 48 THREE MAJOR TYPES OF ANEMIA</i>	98
<i>TABLE 49 ANEMIA: MAJOR CATEGORIES</i>	99
<i>TABLE 50 SYMPTOMS OF ANEMIA</i>	100
<i>TABLE 51 TYPES OF ANEMIA</i>	101
MEGALOBLASTIC ANEMIAS	102
Cobalamin Deficiency	102
<i>TABLE 52 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY</i>	103
Folate Deficiency	103
<i>TABLE 53 DRUGS: CAUSE OF FOLATE DEFICIENCY</i>	104
DIAGNOSTIC TESTS	104
Schilling Test	104
Serum Ferritin and Iron Studies	105
Other Tests	105
TREATMENT	105
HEMOGLOBIN DISORDERS	106
THALASSEMIA	106
SICKLE-CELL ANEMIA	106
<i>TABLE 54 KEY FACTS</i>	107
Causes	107
World Health Organization's Resolutions	108
HEMOLYTIC ANEMIA	108
<i>TABLE 55 LAB TESTS FOR ANEMIA</i>	108
Treatment	109
Anemia Medications	109
HEMOSTASIS	110
HEMOSTASIS: STEPS OF MECHANISM	110
<i>TABLE 56 HEMOSTASIS: THREE MAJOR STEPS</i>	111
TYPES OF HEMOSTASIS	111
Hemostasis in Emergency Medicine	111
ARTIFICIAL HEMOSTASIS	112
<i>TABLE 57 DRUGS THAT EFFECT ACTIVITY OF PLATELETS</i>	113
<i>TABLE 58 ANTICOAGULANTS THAT ACT ON THROMBIN</i>	113
BLEEDING DISORDERS	114
<i>TABLE 59 BLEEDING DISORDERS</i>	114
<i>TABLE 60 BLEEDING DISORDERS: SYMPTOMS</i>	115
<i>TABLE 61 SIGNS AND TESTS</i>	115

TOPIC	PAGE NO.
HEMOPHILIA	115
<i>TABLE 62 KEY CHARACTERISTICS: HEMOPHILIA</i>	116
CLASSIFICATION	117
HISTORICAL BACKGROUND	117
The Clotting Cascade	118
Hemorrhage	118
Natural Inhibitors	119
ACQUIRED HEMOPHILIA	119
FORMS OF HEMOPHILIA	119
Symptoms and Complications	120
Diagnosis	120
Genetic Testing	121
Treatment	121
<i>TABLE 64 MEDICATIONS FOR TREATING HEMOPHILIA</i>	125
Factor VIII Products	125
<i>TABLE 65 FACTOR VIII PRODUCTS</i>	126
Antifibrinolytics	126
<i>TABLE 66 ANTIFIBRINOLYTICS</i>	126
Antihemophilic Agents	126
<i>TABLE 67 ANTIHEMOPHILIC AGENTS</i>	127
Coagulation Factor VIIa, Recombinants	127
Factor VIIa, Recombinant (NovoSeven)	127
Monoclonal Antibodies	127
Rituximab (Rituxan)	128
VON WILLEBRAND DISEASE	128
Symptoms and Diagnosis	128
Treatment	128
THROMBOPHILIA	129
Diagnosis and Treatment	129
THROMBOSIS	130
<i>TABLE 68 FORMATION OF THROMBUS</i>	131
DEEP VEIN THROMBOSIS AND TREATMENT	131
Heparin	131
Warfarin	132
SUPERFICIAL THROMBOPHLEBITIS	132
DEEP VENOUS THROMBOSIS	132
Tests	132
Treatment	133
Surgery	133
HEREDITARY HEMORRHAGIC TELANGIECTASIA	133
ERYTHROCYTOSIS	134
ABSOLUTE POLYCYTHEMIA	134
Primary Polycythemia	134
Secondary Polycythemia	135
Chuvash Polycythemia	135
Relative Polycythemia	136
WHITE BLOOD CELL DISORDERS	136

TOPIC	PAGE NO.
TREATMENT	136
NEUTROPENIA	137
Causes	137
<i>TABLE 69 CAUSES FOR NEUTROPENIA</i>	137
Symptoms and Diagnosis	138
Treatment	138
NEUTROPHILIA	139
BLOOD DISORDERS AFFECTING PLATELETS	139
<i>TABLE 70 WHITE BLOOD CELLS AND DISEASES</i>	139
THROMBOCYTOPENIA	140
Treatment	140
LYMPHOCYTOPENIA	140
Treatment	141
LYMPHOCYTIC LEUKOCYTOSIS	141
MONOCYTOSIS	141
THROMBOCYTHEMIA AND THROMBOCYTOSIS	141
Primary Thrombocythemia	141
Secondary Thrombocytosis	142
<i>TABLE 71 CAUSE OF SECONDARY THROMBOCYTOSIS</i>	143
Symptoms	143
<i>TABLE 72 DIAGNOSTIC TESTS</i>	144
Treatment	144
<i>TABLE 73 MEDICINES FOR THROMBOCYTHEMIA</i>	145
THROMBOCYTOPENIA	145
Causes	145
<i>TABLE 74 CAUSES OF THROMBOCYTOPENIA</i>	146
RARE CONDITIONS THAT CAUSE BLOOD CLOTS	147
Signs and Symptoms	147
<i>TABLE 75 SIGNS OF EXTERNAL BLEEDING</i>	147
Tests	148
Treatment	148
SEVERE THROMBOCYTOPENIA	148
EOSINOPHILS AND DISORDERS	148
<i>TABLE 76 COMMON DRUGS TO TREAT EOSINOPHILIA</i>	149
BASOPHILS AND DISORDERS	149
PLASMA CELL DISORDERS	150

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	8
TABLE 2 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER	10
TABLE 3 KEY CLINICAL FEATURES OF UTERINE CANCER	12
TABLE 4 HISTOLOGY OF ADENOCARCINOMA	13
TABLE 5 RISK FACTORS	15
TABLE 6 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC)	18
TABLE 7 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC GROUPS	19
TABLE 8 CARCINOMA OF THE ENDOMETRIUM	21
TABLE 9 SIGNS AND SYMPTOMS	22
TABLE 10 UTERINE CANCER: DIAGNOSIS	22
TABLE 11 DIAGNOSTIC TESTS	23
TABLE 12 STAGES OF ENDOMETRIAL CANCER	23
TABLE 13 TREATMENT DEPENDS UPON THE STAGE	25
TABLE 14 FIVE-YEAR SURVIVAL RATES (%)	27
TABLE 15 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%)	28
TABLE 16 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 (\$ MILLIONS)	33
TABLE 17 MAIN TYPES OF CANCER AND MORTALITY	34
TABLE 18 CANCER: KEY FACTS	35
TABLE 19 PREVENTION STRATEGIES	36
TABLE 20 CURRENT SCREENING METHODS	37
TABLE 21 NONCOMMUNICABLE DISEASES ACTION PLAN	38
TABLE 22 HISTORY	38
TABLE 23 CERVICAL CANCER SYMPTOMS	40
TABLE 24 ADVANCED CERVICAL CANCER SYMPTOMS	41
TABLE 25 DIAGNOSIS OF CERVICAL CANCER	41
TABLE 26 RISK FACTORS FOR CERVICAL CANCER	42
TABLE 27 CERVICAL CANCER STAGING	42
TABLE 28 GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 (\$ MILLIONS)	49
TABLE 29 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008	52
TABLE 30 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER	60
TABLE 31 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI	61
TABLE 32 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER	62
TABLE 33 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION	64
TABLE 34 OVARIAN CANCER DRUGS AND DIAGNOSTICS-GLOBAL MARKETS, THROUGH 2018 (\$ MILLIONS)	76
TABLE 35 OVARIAN CANCER FACTS	78
TABLE 36 TYPES OF OVARIAN CANCERS	78
TABLE 37 OVARIAN TUMORS METASTASIS	79
TABLE 38 MAIN RISK FACTORS FOR OVARIAN CANCER	80
TABLE 39 HIGH-RISK FACTORS	81
TABLE 40 PREVENTIVE FACTORS	82
TABLE 41 OVARIAN CANCER SYMPTOMS	83
TABLE 42 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017 (\$ MILLIONS)	94

TABLE HEADING	PAGE NO.
TABLE 43 KEY BLOOD DISORDERS	95
TABLE 44 MALIGNANT BLOOD DISORDERS	95
TABLE 45 NON-MALIGNANT BLOOD DISORDERS	96
TABLE 46 TYPE OF BLOOD CELLS AND FUNCTIONS	97
TABLE 47 BLOOD CELLS AND FUNCTION	98
TABLE 48 THREE MAJOR TYPES OF ANEMIA	98
TABLE 49 ANEMIA: MAJOR CATEGORIES	99
TABLE 50 SYMPTOMS OF ANEMIA	100
TABLE 51 TYPES OF ANEMIA	101
TABLE 52 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY	103
TABLE 53 DRUGS: CAUSE OF FOLATE DEFICIENCY	104
TABLE 54 KEY FACTS	107
TABLE 55 LAB TESTS FOR ANEMIA	108
TABLE 56 HEMOSTASIS: THREE MAJOR STEPS	111
TABLE 57 DRUGS THAT EFFECT ACTIVITY OF PLATELETS	113
TABLE 58 ANTICOAGULANTS THAT ACT ON THROMBIN	113
TABLE 59 BLEEDING DISORDERS	114
TABLE 60 BLEEDING DISORDERS: SYMPTOMS	115
TABLE 61 SIGNS AND TESTS	115
TABLE 62 KEY CHARACTERISTICS: HEMOPHILIA	116
TABLE 64 MEDICATIONS FOR TREATING HEMOPHILIA	125
TABLE 65 FACTOR VIII PRODUCTS	126
TABLE 66 ANTIFIBRINOLYTICS	126
TABLE 67 ANTIHEMOPHILIC AGENTS	127
TABLE 68 FORMATION OF THROMBUS	131
TABLE 69 CAUSES FOR NEUTROPENIA	137
TABLE 70 WHITE BLOOD CELLS AND DISEASES	139
TABLE 71 CAUSE OF SECONDARY THROMBOCYTOSIS	143
TABLE 72 DIAGNOSTIC TESTS	144
TABLE 73 MEDICINES FOR THROMBOCYTHEMIA	145
TABLE 74 CAUSES OF THROMBOCYTOPENIA	146
TABLE 75 SIGNS OF EXTERNAL BLEEDING	147
TABLE 76 COMMON DRUGS TO TREAT EOSINOPHILIA	149

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
FIGURE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	9
FIGURE 2 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 (\$ MILLIONS)	33
FIGURE 3 MAIN TYPES OF CANCER AND MORTALITY	34
FIGURE 4 GLOBAL PROSTATE CANCER MARKET, 2010-2017 (\$ MILLIONS)	49
FIGURE 5 OVARIAN CANCER DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2012-2018 (\$ MILLIONS)	76
FIGURE 6 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017 (\$ MILLIONS)	94